Expression of CYP3A5*3 & CYP1A1*2C polymorphism in adult patient with acute myeloid leukaemia & relation with clinical response / Sherine Abdelmoneim Abotaha ; Supervised Nahed Abdelwahab Mohamed , Roxan Ezzat Shafik , Nevine Fawzy Shafik
Material type:
- فى مرضى السرطان اللا ليمفاوى الحاد و علاقته بالا ستجابه الاكلينيكية CYP1A1*2C & CYP3A5*3 تمثيل جين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.03.Ph.D.2017.Sh.E (Browse shelf(Opens below)) | Not for loan | 01010110074134000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.03.Ph.D.2017.Sh.E (Browse shelf(Opens below)) | 74134.CD | Not for loan | 01020110074134000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Background: Genetic variations are one of the important factors in the development of acute leukemia. Molecular studies have proved that genetic polymorphism of metabolic enzymes influence the risk of a variety of tumors including leukemia. Cytochrome P450 (CYP) enzyme catalyzes the phase I metabolism reaction which metabolize endogenous and exogenous DNA-reactive chemical compounds and xenobiotics which could induce genotoxicity and increase the risk for leukemia. Aim of the study: To detect the frequency of CYP3A5*3 and CYP1A1*2C polymorphisms in Egyptian acute myeloid leukemia (AML) patients and to determine the role of genotypes variants as a risk factor for developing leukemia. Patient and Method: Detection of CYP3A5*3 and CYP1A1*2C polymorphisms using PCR-RFLP method in 70 newly diagnosed AML cases and 30 age and sex comparable healthy controls. Results: we found that CYP3A5*3 polymorphism (3/3) and (1/3) genotypes were significantly elevated in AML group compared to control group (p=0.002). However, no statistical significant differences were found between patients and control group as regard CYP1A1*2C polymorphism. Conclusion: Results suggest that Egyptians carrying CYP3A5*3 polymorphism might have an increased risk of AML emphasizing the significance of effective phase I detoxification in carcinogenesis
Issued also as CD
There are no comments on this title.